Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia IncfiledCriticalMyokardia Inc
Publication of AR112406A1publicationCriticalpatent/AR112406A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Reivindicación 1: Un método para tratar la miocardiopatía hipertrófica (MH) en un sujeto que lo necesita, donde el método comprende administrar una cantidad terapéuticamente eficaz de Compuesto 1, que tiene la fórmula (1), o una sal farmacéuticamente aceptable de este, a tal sujeto, donde tal cantidad terapéuticamente eficaz es una dosificación diaria total de alrededor de 1 mg a 50 mg.Claim 1: A method of treating hypertrophic cardiomyopathy (HM) in a subject in need thereof, wherein the method comprises administering a therapeutically effective amount of Compound 1, having the formula (1), or a pharmaceutically acceptable salt thereof, to such a subject, where such therapeutically effective amount is a total daily dosage of from about 1 mg to 50 mg.
ARP1801022352017-08-042018-08-06
TREATMENT OF MH WITH PYRIMIDINADIONE COMPOUNDS
AR112406A1
(en)